Mr. Gilles Gagnon reports

CEAPRO INC. ANNOUNCES DOSING OF FIRST PATIENTS IN PHASE 1-2A STUDY ASSESSING FLAGSHIP PRODUCT AVENANTHRAMIDES FOR POTENTIAL APPLICATIONS IN INFLAMMATION BASED DISEASES

Ceapro Inc. has commenced patient dosing in its phase 1-2a study evaluating its flagship product, avenanthramides, for potential applications in managing conditions related to inflammation. No adverse reactions have been observed and the study can be pursued as per protocol design.

"The start of patient dosing in the phase 1-2a study is a significant accomplishment and step forward in providing a promising new therapeutic in low-grade systemic inflammation," stated Gilles Gagnon, MSc, MBA, president and chief executive officer of Ceapro. "We are pleased with this rapid dosing stage of the study being led by Dr. Tardif and his team. We remain dedicated to advancing medical innovation and addressing unmet medical needs."

The phase 1-2a study (AvenActive) is a double-blind, placebo-controlled, randomized, adaptive, first-in-human study designed to assess safety, tolerability and pharmacokinetics of single and multiple ascending oral doses of avenanthramide. Seventy-two healthy subjects will be enrolled in the phase 1 portion of the trial. The single ascending dose (SAD) arm will include six cohorts of eight healthy subjects, while the multiple ascending dose (MAD) arm will include three cohorts of eight healthy subjects. Following the phase 1 portion, pending successful results, the AvenActive protocol also includes a phase 2a portion for patients presenting evidence of mild to moderate inflammation. Twenty-four patients would be enrolled in the phase 2a portion.

The phase 1-2a trial is designed to evaluate the safety profile of avenanthramides and gather initial insights into its potential efficacy. As the trial progresses, Ceapro remains focused on collaborating with regulatory authorities, health care professionals and patient communities to bring this innovative therapy to market.

About Ceapro Inc.

Ceapro is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical and therapeutics products for humans and animals. The company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions.

We seek Safe Harbor.